Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors ? -- A literature-based meta-analysis

<p>Abstract</p> <p>Background</p> <p>In the first line treatment of non-small cell lung cancer (NSCLC), several clinical trials have shown that not all NSCLC patients can benefit from treatment with tyrosine kinase inhibitors (TKIs) than receiving chemotherapy. Some tri...

Full description

Bibliographic Details
Main Authors: Xu Chongrui, Zhou Qing, Wu Yi-long
Format: Article
Language:English
Published: BMC 2012-10-01
Series:Journal of Hematology & Oncology
Subjects:
Non-small cell lung cancer
Target therapy
Chemotherapy
Meta-analysis
Online Access:http://www.jhoonline.org/content/5/1/62

Internet

http://www.jhoonline.org/content/5/1/62

Similar Items